GLP-1 / Metabolic
Heat-R
GLP/GIP/Glucagon Tri-Agonist
$99.00
Size
9 in stock · 10 mg per vial
Description
Triple receptor agonist targeting GLP-1, GIP, and glucagon pathways. Studied for metabolic and body composition research.
Research
Retatrutide is a novel triple agonist targeting GLP-1, GIP (glucose-dependent insulinotropic polypeptide), and glucagon receptors simultaneously. Early-phase research suggests this tri-agonist approach produces additive metabolic effects beyond dual or single agonists. Preclinical studies show pronounced reductions in body weight, hepatic fat content, and improvements in lipid profiles. The glucagon component is thought to enhance energy expenditure and hepatic fat oxidation, while GLP-1 and GIP components drive insulin secretion and appetite suppression. Phase 2 clinical research has reported substantial weight reduction outcomes. Ongoing studies are investigating its effects on NASH, cardiovascular risk factors, and long-term metabolic remodeling. For research use only.
RESEARCH USE ONLY. Not for human or veterinary consumption. This product is sold to qualified researchers aged 21 or older for laboratory research purposes.